- Home
- TBPH vs EE Comparison
TBPH vs EE Comparison
Compare TBPH & EE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBPH
- EE
- Stock Information
- Founded
- TBPH 2013
- EE 2003
- Country
- TBPH United States
- EE United States
- Employees
- TBPH N/A
- EE N/A
- Industry
- TBPH Biotechnology: Pharmaceutical Preparations
- EE Oil/Gas Transmission
- Sector
- TBPH Health Care
- EE Utilities
- Exchange
- TBPH Nasdaq
- EE Nasdaq
- Market Cap
- TBPH 699.0M
- EE 786.2M
- IPO Year
- TBPH N/A
- EE 2022
- Fundamental
- Price
- TBPH $13.95
- EE $23.70
- Analyst Decision
- TBPH Strong Buy
- EE Buy
- Analyst Count
- TBPH 3
- EE 7
- Target Price
- TBPH $21.33
- EE $32.86
- AVG Volume (30 Days)
- TBPH 602.7K
- EE 511.4K
- Earning Date
- TBPH 08-12-2025
- EE 11-05-2025
- Dividend Yield
- TBPH N/A
- EE 1.35%
- EPS Growth
- TBPH N/A
- EE 18.98
- EPS
- TBPH 0.26
- EE 1.33
- Revenue
- TBPH $77,205,000.00
- EE $987,637,000.00
- Revenue This Year
- TBPH $78.36
- EE $31.19
- Revenue Next Year
- TBPH N/A
- EE $25.16
- P/E Ratio
- TBPH $54.52
- EE $17.82
- Revenue Growth
- TBPH 24.49
- EE 9.86
- 52 Week Low
- TBPH $7.88
- EE $17.70
- 52 Week High
- TBPH $14.55
- EE $32.99
- Technical
- Relative Strength Index (RSI)
- TBPH 71.41
- EE 41.54
- Support Level
- TBPH $13.66
- EE $23.26
- Resistance Level
- TBPH $14.55
- EE $25.17
- Average True Range (ATR)
- TBPH 0.46
- EE 0.66
- MACD
- TBPH -0.02
- EE 0.04
- Stochastic Oscillator
- TBPH 56.20
- EE 24.23
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
About EE Excelerate Energy Inc.
Excelerate Energy Inc offers LNG solutions, providing integrated services along the LNG value chain. It offers a full range of regasification services, from FSRUs to infrastructure development, to LNG and natural gas supply. Its business spans the globe, with a regional presence in 11 countries and an operational presence in Argentina, Bangladesh, Brazil, Finland, Germany, Pakistan, the United Arab Emirates (UAE), and the United States.